Dermata Therapeutics (DRMA)Director sold ~$13

~$13

Approx. value · 11 sh @ $1.19

Traded

Jun 16, 2026

Filed

Jun 16, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Mar 31, 2026Company filing · Form 8-K · ResultsReported its results
2. May 27, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On May 27, 2026, Dermata Therapeutics, Inc. (the “ Company ”) held its 2026 Annual Meeting of Stockholders (the “ Annual Meeting ”). At the Annual Meeting, shareholders approved an amendment to the Company’s 2021 Omnibus Equity Incentive Plan (the “ 2021 Plan ”) to increase the number of shares available for issuance thereunder to 402,214 shares (the “ Plan Amendment ”).”
3. Jun 16, 2026 · this disclosureInsiderDirector sold ~$13 of DRMA shares in the open market

What came next

1. Aug 11, 2026Company filing · Form 8-K · ResultsReported its results
2. Aug 16, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Dermata Therapeutics

OQRO holds no insider, Congress, fund or contract record for Dermata Therapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DRMA page.

Other recent filings by Kathleen D. Scott, Director

• SEC Form 4 at Ars Pharmaceuticals (SPRY)Aug 22, 2025
• SEC Form 4 at Ars Pharmaceuticals (SPRY)May 22, 2025
• SEC Form 4 at Ars Pharmaceuticals (SPRY)Oct 17, 2024

The full history of Kathleen D. Scott, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Dermata Therapeutics

• SEC Form 4Mar 17, 2026

Everything OQRO holds on this company is on its DRMA page.